shifoxor
Shifoxor, also known as TAK-941 or Juvelis, is a small-molecule inhibitor developed for the treatment of acute myeloid leukemia (AML). It works by targeting the mitogen-activated protein kinase kinase kinase (MAP3K) pathway, which plays a crucial role in leukemic cell growth and survival.
Shifoxor was initially discovered by Takeda in 2014 through a collaboration with the University of California,
During the clinical trials, shifoxor showed significant antitumor activity in patients with AML. Specifically, a treatment-induced
Clinical development of shifoxor continued, with multiple subsequent phases initiated. One ongoing, open-label study assesses the
The evolution of shifoxor development reflects a commitment to understanding its therapeutic potential in treating AML.
Individual results may vary as the ongoing clinical trials continue to grow our understanding of the compound.